Last year, Guardant Health Inc generated 683.60M USD for its biggest-performing segment, Oncology. The United States made the largest contribution, accounting for 923.28M USD last year. For the latest quarter, Guardant Health Inc reported the revenue of 219.10M USD for the period ending 2026-06-30, which came from the top-performing segment, Oncology. United States contributed the highest revenue, at 318.04M USD.

By Business

Revenue

Proportion

Annual

Annual

Quarterly

Oncology

Biopharma and data

Screening

Licensing and other

FY2025

Oncology

683.60M(69.61%)

Biopharma and data

210.13M(21.40%)

Screening

79.73M(8.12%)

Licensing and other

8.56M(0.87%)

By Region

Revenue

Proportion

Annual

Annual

Quarterly

United States

International

FY2025

FY2024

FY2023

FY2022

FY2021

FY2020

FY2019

United States

923.28M(94.02%)

697.16M(94.34%)

526.52M(93.36%)

420.62M(93.57%)

352.56M(94.36%)

264.66M(92.30%)

194.31M(90.64%)

International

58.74M(5.98%)

41.85M(5.66%)

37.42M(6.64%)

28.92M(6.43%)

21.09M(5.64%)

22.07M(7.70%)

20.06M(9.36%)